This site is intended for healthcare professionals

FDA authorises restart of the COVID-19 AZD 1222 vaccine US phase III trial.- AstraZeneca

Read time: 1 mins
Last updated:26th Oct 2020
Published:24th Oct 2020
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD 1222, have resumed across the world with regulators in the US, UK, Brazil, South Africa and Japan confirming that it was safe to do so. The FDA authorised the restart in the US, following the resumption of trials in other countries in recent weeks.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest